PharmaResearch Stock Price & Chart

KRX: 214450 · 파마리서치 · KOSPI

₩375,500▲ ₩5,500 (+1.49%)at close · July 28, 2026
713,000255,000375,500Jul 04, 25Oct 13Jan 15Apr 21Jul 28, 26

PharmaResearch (파마리서치, KRX: 214450) last closed at ₩375,500 on July 28, 2026, a +1.49% move on the day. Over the trailing 52 weeks the stock has traded between ₩255,000 and ₩713,000, a -34.58% change over the past year. Figures are end-of-day closing prices from the Korea Exchange.

Last close₩375,500
Day change+1.49%
52-week high₩713,000
52-week low₩255,000

Key Fundamentals

FY 2026.03
Market cap₩3.90T
P/E (PER)26.43
P/B (PBR)6.30
EPS₩14,209
BPS₩59,603
ROE27.99%
Debt ratio48.18%
Rev. growth24.97%

P/E, P/B and market cap are computed from the latest close; EPS, BPS, ROE and debt ratio are the most recent reported figures (FY 2026.03) from the Korea Investment & Securities Open API. Informational only, not investment advice.

Technical Snapshot

as of 2026-07-28
BullishAlgorithmic summary of 5 standard indicators (net score +5). Describes current technical posture only — not a buy or sell recommendation.
  • ▲ Bullish20-day MAPrice above 340,375
  • ▲ Bullish60-day MAPrice above 317,775
  • ▲ Bullish120-day MAPrice above 324,354
  • ▲ BullishMA trend (20 vs 60)Short-term above mid-term
  • · NeutralRSI (14)RSI 59 — neutral zone
  • ▲ BullishMACD (12,26,9)MACD above signal
52-week position: 26% of rangeRSI(14): 595-day volume vs 20-day: -3%

Indicators are computed mechanically from end-of-day prices. They are provided for informational purposes only, are not investment advice or a recommendation, and past performance does not indicate future results.

Reports mentioning PharmaResearch

No daily reports have covered PharmaResearch yet. New reports appear here automatically when the stock is featured.

← Back to all Korean stocks

Price history is sourced from the Korea Exchange via the Korea Investment & Securities Open API and updated after each trading session. This page is provided for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Data may be delayed or contain errors — verify with an official source before trading.